| Ticker: MLNM | 640 Memorial Drive | |
| Exchange: NASDAQ-National Market | Cambridge, Massachusetts 02139 | |
| Industry: Manufacturing | (617) 679-7000 |
| Type of Shares: | Common Shares | Filing Date: | 3/19/96 | |
| U.S. Shares: | 4,500,000 | Offer Date: | 5/6/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $9.00 - $11.00 | |
| Primary Shares: | 4,500,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $45,000,000 | Selling: | $0.47 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 22,837,678 |
| Manager | Tier | Phone |
| Goldman, Sachs & Co. | Lead Manager | (212) 902-1172 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $22.88 | Assets: | $25.11 | ||
| Net Income: | $1.28 | Liabilities: | $12.01 | ||
| EPS: | $0.07 | Equity: | $13.10 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a bio-pharmaceutical company engaged in the commercial application of genetics to therapeutic and diagnostic products in an effort toward developing a genetically based slimming drug to treat obesity. The Company also focused in research efforts on identifying and elucidating the function of genes responsible diseases such as type II diabetes, atherosclerosis, asthma, cancer and diseases of the central nervous system. The Company's principal objective is to use its technology platform to enable and accelerate the discovery and development of new, proprietary therapeutic and diagnostic products capable of addressing these diseases at their root causes, rather than simply identifying and treating their symptoms. The Company is distinctive in the genomics industry in employing a comprehensive technology platform that couples multiple synergistic approaches for identifying disease genes with a broad set of bench and computational biology technologies for elucidating the function of these genes and their role in disease initiation and progression. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development, working capital, and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.